S.A. Mason LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

S.A. Mason LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,420 shares of the company’s stock after purchasing an additional 117 shares during the quarter. S.A. Mason LLC’s holdings in Johnson & Johnson were worth $1,174,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Pathway Financial Advisors LLC raised its holdings in Johnson & Johnson by 4.3% in the fourth quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after acquiring an additional 226 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Johnson & Johnson by 5.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after acquiring an additional 15,490 shares in the last quarter. OneAscent Financial Services LLC raised its holdings in Johnson & Johnson by 82.8% in the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after acquiring an additional 4,457 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its holdings in Johnson & Johnson by 12.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after acquiring an additional 2,201 shares in the last quarter. Finally, TrueMark Investments LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $1,458,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on JNJ. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective on the stock. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Bank of America cut their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $174.07.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.38 during trading on Thursday, hitting $147.20. 257,102 shares of the company were exchanged, compared to its average volume of 7,350,285. The company has a market cap of $354.26 billion, a price-to-earnings ratio of 9.15, a PEG ratio of 2.45 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm’s fifty day moving average price is $148.13 and its 200 day moving average price is $154.24. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.68 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. The ex-dividend date was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.